37TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Abbott

January 8, 2019

Brian Yoor
Executive Vice President, Finance and CFO
FORWARD LOOKING STATEMENT

Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors,” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2017, and in the interim reports filed on Form 10-Q for subsequent quarterly periods, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Sustainable Organic Sales Growth

• Strategic Shaping
• Exciting New Product Opportunities
  – Libre®
  – Alinity™
  – Structural Heart
• Rich Pipeline
• Improvement in Core Businesses
FreeStyle Libre
Changing the way diabetes is managed

• Rapid patient adoption
• Projected sales > $1 billion in 2018
• Significant long-term growth opportunity with ~400 million diabetics worldwide
• Robust R&D pipeline
Alinity
Bold leap forward in diagnostic testing

• Full suite of diagnostic instruments
• Offers significant innovation
  – Smaller footprint
  – Faster cycle time
  – Greater automation
  – Easier to operate
  – Lower service costs
• Strong uptake in Europe
• Launching in the U.S.
• Multi-year growth driver
Structural Heart
Leading portfolio of minimally invasive transcatheter solutions

Mitral Valve Repair (MitraClip®)
• MitraClip is the leading mitral repair device
• Pursuing U.S. label expansion in 2019
• Steady cadence of innovation planned

Mitral Valve Replacement (Tendyne™)
• Completed enrollment in CE Mark trial
• U.S. pivotal trial initiated 3Q18

Tricuspid Valve Repair (TriClip™)
• Completed enrollment in CE Mark trial
• Plan to initiate U.S. pivotal trial in 2019

Aortic Valve Replacement (Portico™)
• U.S. pivotal trial on-going

Left Atrial Appendage (Amulet™)
• U.S. pivotal trial on-going
Well-balanced capital allocation delivers strong shareholder returns

- Returning cash to shareholders
- Prudently managing our balance sheet
- Investing for future growth